Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016’, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
  • The report reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Uterine Leiomyoma (Uterine Fibroids) therapeutics and enlists all their major and minor projects
  • The report assesses Uterine Leiomyoma (Uterine Fibroids) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) Overview
Therapeutics Development
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
Bayer AG
BioSpecifics Technologies Corp.
Dongkook Pharmaceutical Co., Ltd.
Euroscreen S.A.
Kissei Pharmaceutical Co., Ltd.
Laboratoire HRA Pharma
Repros Therapeutics Inc.
Takeda Pharmaceutical Company Limited
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
collagenase clostridium histolyticum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Endometriosis and Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVE-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relugolix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telapristone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triptorelin biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulipristal acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vilaprisan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPEA-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Featured News & Press Releases
May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
Dec 21, 2015: Repros Updates Proellex Program
Nov 12, 2015: Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex in Women With Symptomatic Uterine Fibroid Bleeding
Oct 09, 2015: Full Results of PEARL IV Study Presented at the European Society of Gynaecological Endoscopy Congress Confirms the Efficacy of Ulipristal Acetate 5 mg for the Long Term Management of Uterine Fibroids
Sep 16, 2015: Abbvie Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids
May 28, 2015: European Commission approves Esmya 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA
Dec 29, 2014: Repros Initiates Two Phase 2B Uterine Fibroid Studies
Oct 16, 2014: BioSpecifics Technologies Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2016
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc., H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp., H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Euroscreen S.A., H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc., H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2016
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2016
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook